General Session

General Session - The Science of GLP-1 Receptor Agonists: A Rising Tide in Addiction Treatment

Friday, April 25, 2025

4:30 PM – 5:45 PM

Presenter(s)

Sarah E. Wakeman, MD, FASAM

Associate Professor/Senior Medical Director
Mass General Brigham
Boston, Massachusetts
SW

Stephanie T. Weiss, MD, PhD, FAACT, FASAM

Staff Research Physician
National Institute on Drug Abuse Intramural Research Program
National Institute on Drug Abuse Intramural Research Program
Baltimore, Maryland
Luba Yammine, PhD, APRN, FNP-C

Associate Professor
University of Texas Health Science Center at Houston
UTHealth Houston McGovern Medical School, Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences
Houston, Texas
Joji Suzuki, MD

Director, Division of Addiction Psychiatry
Brigham and Women's Hospital
Boston, Massachusetts

This session explores the groundbreaking potential of GLP-1 receptor agonists in treating substance use disorders. Attendees will gain insights into the history of this medication, mechanisms of action, clinical applications, and the transformative impact these therapies can have on recovery outcomes. After brief presentations from experts investigating the application of GLP-1 receptor agonists for the treatment of alcohol, nicotine and opioid use disorders, presenters will engage in a lively moderated panel to discuss future implications for research, and potential limitations to this treatment option. Join us to dive into the rising tide of innovation and the future of addiction treatment.

Disclosure(s):

Sarah E. Wakeman, MD, FASAM: No financial relationships to disclose

Stephanie T. Weiss, MD, PhD, FAACT, FASAM: No financial relationships to disclose

Luba Yammine, PhD, APRN, FNP-C: Eli Lilly: Consultant/Advisory Board (Ongoing); Novo Nordisk: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Joji Suzuki, MD: Indivior: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Terminated, August 1, 2023)